Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29185517 | 0.80 | SMN1; SMN2 (0.67) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL21609607 | 0.68 | LMNA (0.51) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL29185522 | 0.68 | SMN1; SMN2 (0.70) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL19382006 | 0.66 | NPC1 (0.49) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL29185512 | 0.66 | LMNA (0.67) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL29185508 | 0.64 | LMNA (0.53) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL12918495 | 0.64 | POLB (0.55) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL6417991 | 0.62 | NPC1 (0.45) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL29185505 | 0.62 | ALDH1A1 (0.67) | LMNARAB9ASMN1; SMN2NPC1NPSR1 | |
| SCHEMBL10560991 | 0.62 | TSHR (0.54) | LMNARAB9ASMN1; SMN2NPC1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250268821-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | AVALYN PHARMA INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250177294-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | AVALYN PHARMA INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4531809-A2 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | Avalyn Pharma Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | SPITFIRE PHARMA LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4506017-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | Mederis Diabetes, LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | SPITFIRE PHARMA LLC (MD) | 2024-12-24 | — | — | US | disclosed |
| EP-3735295-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240269238-A1 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-05-09 | — | — | US | disclosed |
| WO-2023235267-A2 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | AVALYN PHARMA INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11600045-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2023-03-07 | — | — | US | disclosed |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | ALTIMMUNE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220366648-A1 | Collaborative Light Show Authoring for Tessellated Geometries | CONTRAVENTUM, LLC (US) | 2022-11-17 | — | — | US | disclosed |
| US-11282276-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | LMNA 2458/4885RAB9A 1322/4885SMN1; SMN2 3472/4885 |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | GLP1R, GCGR, GIPR | LMNA 3781/4885RAB9A 1438/4885SMN1; SMN2 2519/4885 |
| US-20250268821-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | INF2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IPO5 | LMNA 3120/4885RAB9A 2535/4885SMN1; SMN2 261/4885 |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | LMNA 3781/4885RAB9A 1438/4885SMN1; SMN2 2519/4885 |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | GIPR, GLP1R, GCGR | LMNA 3569/4885RAB9A 996/4885SMN1; SMN2 2492/4885 |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | LMNA 1854/4885RAB9A 2361/4885SMN1; SMN2 2879/4885 |
| US-20240269238-A1 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | LMNA 2785/4885RAB9A 1630/4885SMN1; SMN2 2183/4885 |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | LMNA 1854/4885RAB9A 2361/4885SMN1; SMN2 2879/4885 |
| US-20230218564-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | LMNA 1854/4885RAB9A 2361/4885SMN1; SMN2 2879/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | LMNA 3600/4885RAB9A 1501/4885SMN1; SMN2 2299/4885 |
| US-20250177294-A1 | NINTEDANIB AND NINTEDANIB COMBINATION DRY POWDER COMPOSITIONS AND USES | INF2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IPO5 | LMNA 3120/4885RAB9A 2535/4885SMN1; SMN2 261/4885 |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | LMNA 1854/4885RAB9A 2361/4885SMN1; SMN2 2879/4885 |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | LMNA 3781/4885RAB9A 1438/4885SMN1; SMN2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.